EATONTOWN, NJ / ACCESSWIRE / March 20, 2019 / American CryoStem Corporation (OTC PINK: CRYO) a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular products and technologies for the Regenerative and Personalized Medicine industries, today announced that it has completed a Cooperative Framework Agreement with Shonan Beauty Clinic, and MEDINET Co., Ltd. which will provide CRYO with greater access to Japanese consumers for its ATGRAFT®Tissue Processing and Storage, Regenerative Medicine products and cellular platform services.
Shonan Beauty Clinic (www.s-b-c.net) is the largest chain of plastic surgery clinics in Japan. Available treatments include breast augmentation, liposuction, fat transfer, skin care, gynecology, whitening, hair transplant, eyelids and gender-change operations.
MEDINET Co., Ltd. (www.medinet-inc.co.jp) is one of the largest cell-processing enterprises and established Contract Development and Manufacturing organizations (CDMO) based in Yokohama, Japan. MEDINET possesses a GMP (Good Manufacturing Practice) / GCTP (Good Gene, Cellular, and Tissue-based Products Manufacturing Practice) compliant facility and provides a variety of services including cell processing and process development from the pre-clinical research stage to the commercialization stage. MEDINET services medical institutions, research facilities, and biopharmaceutical companies for the biotech industry.
The Agreement outlines the parties responsibilities and general terms for the implementation of the Company’s core ATGRAFT® tissue, collection, processing and banking platform services to be delivered through the Shonan Beauty Clinic’s chain of 90 clinics with MEDINET as a CDMO. Financial terms are subject to final Licensee Agreements to be executed between the parties.
John Arnone, Chairman, and CEO of American CryoStem commented, ”We continue to be focused on our international operations in locations that have large consumer bases interested in natural beauty solutions in the plastic, cosmetic and aesthetic surgical enhancement and regenerative market. We look forward to the successful implementation of our ATGRAFT®platform through Shonan and Medinet to expand our presence in Japan.”
For further detailed Corporate or Regenerative Medicine information please visit:
This press release may contain forward-looking statements, including information about management’s view of American CryoStem Corporation’s (“the Company”) future expectations, plans and prospects. In particular, when used in the preceding discussion, the words “believes,” “expects,” “intends,” “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.
SOURCE: American CryoStem Corporation
View source version on accesswire.com: